Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19. SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).
In addition, the independent Data Safety Monitoring Board has reviewed the safety data from the first cohort and supports continuation of the study and dose escalation.
“We are pleased to have reached this milestone in our evaluation of SBI-101 for the treatment of severe COVID-19,” said Sentien CEO, Brian Miller. “We are grateful to the patients and clinical site investigators and staff for their participation in the study and we look forward to continued collaboration as we commence enrollment of the second cohort.”